A comparative pharmacokinetic and pharmacodynamic study of two novel Cuban PEGylated rHuEPO MIRCERA and iorEPOCIM.

Context: The recombinant human erythropoietin (rHuEPO) stimulates the erythropoiesis process. Because this glycoprotein has a short half-life, it needs to be administrated two to three times a week. One of the technics to solve this issue is the PEGgilation.